Skip to content

NeuroOne Medical Technologies Corporation: 10-Q filed 2013-11-15

What NeuroOne Medical Technologies Corporation reported in its quarterly report filed 2013-11-15 (fiscal Q3 2013): 15 published measures, 50 facts as tagged in accession 0001014897-13-000417.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-15
Fiscal period
fiscal Q3 2013
Accession
0001014897-13-000417 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuroOne Medical Technologies Corporation filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-30608USD
At 2012-12-311,118USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-09-3028,906USD
At 2012-12-3118,355USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-30-28,298USD
At 2012-12-31-17,237USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-5,131USD92
2013-01-01 to 2013-09-30-27,561USD273
2009-08-20 to 2013-09-30-77,948USD1503
2012-07-01 to 2012-09-30-4,780USD92
2012-01-01 to 2012-09-30-12,535USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-22,510USD273
2009-08-20 to 2013-09-30-68,542USD1503
2012-01-01 to 2012-09-30-12,366USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-3022,000USD273
2009-08-20 to 2013-09-3069,150USD1503
2012-01-01 to 2012-09-300USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-09-300USD273
2009-08-20 to 2013-09-300USD1503
2012-01-01 to 2012-09-300USD274

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-07-01 to 2013-09-304,500,000shares92
2013-01-01 to 2013-09-304,500,000shares273
2012-07-01 to 2012-09-304,500,000shares92
2012-01-01 to 2012-09-304,500,000shares274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-30608USD
At 2012-12-311,118USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-401USD92
2013-01-01 to 2013-09-30-1,051USD273
2009-08-20 to 2013-09-30-1,454USD1503
2012-07-01 to 2012-09-30-49USD92
2012-01-01 to 2012-09-30-169USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-3028,906USD
At 2012-12-3118,355USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-07-01 to 2013-09-304,982USD92
2013-01-01 to 2013-09-3023,619USD273
2009-08-20 to 2013-09-3079,349USD1503
2012-07-01 to 2012-09-304,754USD92
2012-01-01 to 2012-09-3012,927USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2013-07-01 to 2013-09-30252USD92
2013-01-01 to 2013-09-301,109USD273
2009-08-20 to 2013-09-306,855USD1503
2012-07-01 to 2012-09-3023USD92
2012-01-01 to 2012-09-30561USD274

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-09-3044,577USD
At 2012-12-3128,077USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-304,982USD92
2013-01-01 to 2013-09-3023,619USD273
2009-08-20 to 2013-09-3079,349USD1503
2012-07-01 to 2012-09-304,754USD92
2012-01-01 to 2012-09-3012,927USD274

Inspect the source

Entity
NeuroOne Medical Technologies Corporation / CIK 0001500198
Captured
2026-09-20T09:11:29.314Z
SEC response SHA-256
dec08ad6d59f8d84b3a6db4a6ff83df3a276b794fed82089495b0788055433dd

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001500198.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))